Home
About
FAQ
History (24)
Change in Age-Specific, Psychosocial Correlates of Risky Sexual Behaviors Among Youth: Longitudinal Findings From a Deep South, High-Risk Sample.
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Cordectomy for the treatment of posttraumatic syringomyelia. Report of four cases and review of the literature.
Incorporate Language in Medical Education to Address Structural Barriers to Care During the COVID-19 Pandemic and Beyond.
Reduviidae
See All 24 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Results (30)
More Search Options
Sort
Query Relevance
Name (A-Z)
Name (Z-A)
Institution (A-Z)
Institution (Z-A)
Show
(choose columns)
Faculty Rank
Name
Institution
Why
Michael D. Shapiro DO
Wake Forest School of Medicine
Why?
Yashashwi Pokharel MD, MSCR
Wake Forest School of Medicine
Why?
Reto H. Asmis PhD
Wake Forest School of Medicine
Why?
Sanjay K. Gandhi MD
Wake Forest School of Medicine
Why?
Elsayed Z. Soliman MD, MS
Wake Forest School of Medicine
Why?
Cynthia L. Emory MD, MBA
Wake Forest School of Medicine
Why?
Ralph B. D'Agostino PhD, FASA
Wake Forest School of Medicine
Why?
Giuseppe Orlando MD, PhD
Wake Forest School of Medicine
Why?
Joseph Yeboah MD, MS,FACC,FAHA
Wake Forest School of Medicine
Why?
Alain Bertoni MD, MPH
Wake Forest School of Medicine
Why?
Michael Olivier PhD
Wake Forest School of Medicine
Why?
John S. Parks PhD
Wake Forest School of Medicine
Why?
Justin B. Moore PhD, MS
Wake Forest School of Medicine
Why?
James L. Pirkle MD
Wake Forest School of Medicine
Why?
Dorothy L. Long PhD
Wake Forest School of Medicine
Why?
Per Page
15
25
50
100
Page
of 2
Next
Prev
Search Criteria
Dyslipidemias
Click "Why?" to see why a person matched the search.
Search Options
Modify Search
Search Other Institutions